Medullary breast carcinoma

Medullary Breast Carcinoma

Medullary breast carcinoma is a rare subtype of invasive breast cancer that accounts for approximately 3-5% of all breast cancer cases. It is characterized by the presence of distinct histological features and a relatively better prognosis compared to other types of breast cancer.

Symptoms[edit | edit source]

Patients with medullary breast carcinoma may present with a palpable breast lump, changes in breast size or shape, nipple discharge, or skin changes such as redness or dimpling. However, some cases may be asymptomatic and detected through routine screening mammograms.

Diagnosis[edit | edit source]

Diagnosis of medullary breast carcinoma is typically confirmed through a combination of imaging studies such as mammography, ultrasound, and magnetic resonance imaging (MRI), as well as a biopsy of the breast tissue. Histologically, medullary breast carcinoma is characterized by the presence of well-defined borders, high-grade tumor cells with prominent lymphocytic infiltrate, and syncytial growth pattern.

Treatment[edit | edit source]

The treatment approach for medullary breast carcinoma may involve a combination of surgery, chemotherapy, radiation therapy, and targeted therapy. Surgical options include lumpectomy or mastectomy, depending on the size and extent of the tumor. Chemotherapy regimens may be tailored based on the individual's tumor characteristics, and targeted therapies such as HER2 inhibitors may be considered for specific subtypes.

Prognosis[edit | edit source]

Overall, medullary breast carcinoma has a more favorable prognosis compared to other types of breast cancer. The 5-year survival rate for patients with medullary breast carcinoma is estimated to be around 85-90%. However, the prognosis may vary depending on factors such as tumor size, grade, lymph node involvement, and hormone receptor status.